Exposure to sodium channel-inhibiting drugs and cancer survival: protocol for a cohort study using the QResearch primary care database.
BACKGROUND
Metastasis from solid tumours is associated with significant morbidity and mortality, and is the leading cause of cancer-related deaths. Voltage-gated sodium channels (VGSCs) are drug targets for the treatment of epilepsy. VGSCs are also present in cancer cells, where they regulate metastatic cell behaviours, including cellular movement and invasion. Treating cancer cells with the VGSC-inhibiting anticonvulsant phenytoin reduces cellular invasion and migration. Together, these suggest that VGSCs may be useful targets for inhibiting metastasis. The purpose of this study is to test the hypothesis that use of VGSC-inhibiting drugs will reduce metastasis, and therefore increase survival time in patients with cancer.


METHODS
A cohort study based on primary care data from the QResearch database will include patients with one of the three common tumours: breast, bowel and prostate. The primary outcome will be overall survival from the date of cancer diagnosis. Cox proportional hazards regression will be used to compare the survival of patients with cancer taking VGSC-inhibiting drugs (including anticonvulsants and class I antiarrhythmic agents) with patients with cancer not exposed to these drugs, adjusting for age and sex. Exposure to VGSC-inhibiting drugs will be defined as having at least one prescription for these drugs prior to cancer diagnosis. High and low exposure groups will be identified based on the length of use. A number of sensitivity and secondary analyses will be conducted.


BACKGROUND
The protocol has been independently peer-reviewed and approved by the QResearch Scientific Board. The project has also been approved by the University of York Ethical Review Process. The results will be presented at international conferences and published in an open access peer-reviewed journal, in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) criteria.
Department of Health Sciences, University of York, York, UK.
Caroline
C
Fairhurst
Department of Health Sciences, University of York, York, UK Hull York Medical School, York, UK.
Ian
I
Watt
Hull York Medical School, York, UK Department of Biology, University of York, York, UK.
Fabiola
F
Martin
Department of Health Sciences, University of York, York, UK.
Martin
M
Bland
Department of Biology, University of York, York, UK.
William J
http://orcid.org/0000-0001-6882-3351
WJ
Brackenbury
D000328:Adult; D001943:Breast Neoplasms / Q000188:drug therapy*; D002985:Clinical Protocols; D015331:Cohort Studies; D003110:Colonic Neoplasms / Q000188:drug therapy*; D016208:Databases, Factual; D005260:Female; D006801:Humans; D008297:Male; D011320:Primary Health Care / Q000379:methods; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D026941:Sodium Channel Blockers / Q000627:therapeutic use*; D016019:Survival Analysis
D026941:Sodium Channel Blockers
PRIMARY CARE; STATISTICS & RESEARCH METHODS